Results 101 to 110 of about 2,650 (185)

Exploring the Spectrum of VEGF Inhibitors? Toxicities from Systemic to Intra-Vitreal Usage in Medical Practice [PDF]

The use of Vascular Endothelial Growth Factor inhibitors (VEGFi) has become prevalent in the field of medicine, given the high incidence of various pathological conditions necessitating VEGF inhibition within the general population.
Berretta, M., Capuozzo, M., Correra, M., Di Mauro, A., Di Mauro, G., Granata, V., Gualillo, O., Maiolino, P., Nasti, G., Ottaiano, A., Sabbatino, F., Santorsola, M., Vanni, G.   +12 more
core   +1 more source

Real-World Safety Outcomes with Brolucizumab in Neovascular Age-Related Macular Degeneration: Findings from the IRIS® Registry

Ophthalmology and Therapy
Introduction To assess real-world safety outcomes for adults with neovascular age-related macular degeneration (nAMD) treated with brolucizumab from the US-based IRIS® (Intelligent Research in Sight) Registry.
Marco A. Zarbin, Mathew W. MacCumber, Helene Karcher, Eser Adiguzel, Andrew Mayhook, Andrew LaPrise, Ver L. Bilano, Franklin Igwe, Michael S. Ip, Charles C. Wykoff   +9 more
doaj   +1 more source

Real-world evidence for brolucizumab efficacy in age-related macular degeneration and central serous chorioretinopathy patients

Heliyon
Real-world studies concerning different populations are valuable and bring new information regarding different regimens of Brolucizumab injections and their adverse reactions. The present study investigates the efficacy of a pro-re-nata regimen (PRN) for
Samoila Lacramioara, Samoila Ovidiu, Clichici Simona   +2 more
doaj   +1 more source

The Short-term efficacy of a monoclonal antibody fragment (brolucizumab) for treating neovascular age-related macular degeneration

Ukrainian Journal of Ophthalmology
Aim. To evaluate the short-term efficacy of using a monoclonal antibody fragment (Brolucizumab) for treating neovascular age-related macular degeneration, depending on the morphometric parameters of the retina. Methods: This study included 48 patients
A. F. Yusupov, M. Kh. Karimova , S. A. Djamalova , D. K. Makhkamova , S. I. Abdullaeva , M. A. Zakirkhodjaeva, Z. A. Khodjaeva, D. A. Rakhimova   +7 more
doaj   +1 more source

Early Residual Fluid-Free Status and Long-Term BCVA Outcomes: A Treatment Agnostic, Post Hoc Analysis of Pooled HAWK and HARRIER Data [PDF]

, 2022
Eandi, Chiara M
core   +1 more source

Comparative Analysis of Intravitreal Dexamethasone Implant (Ozurdex) and Brolucizumab Injection in the Treatment of Diabetic Macular Edema with Hyperreflective Intraretinal Dots: A Retrospective Study

Clinical Ophthalmology
Somnath Chakraborty,1 Jay Umed Sheth2 1Department of Vitreoretinal Services, Retina Institute of Bengal, Siliguri, West Bengal, India; 2Department of Vitreoretinal Services, Shantilal Shanghvi Eye Institute, Mumbai, Maharashtra, IndiaCorrespondence ...
Chakraborty S, Sheth JU
doaj  

Case Series on Initial Responses to Intravitreal Brolucizumab in Patients with Recalcitrant Chronic Wet Age-Related Macular Degeneration

International Medical Case Reports Journal, 2020
Jaycob Avaylon,1 Sol Lee,2 Ron P Gallemore2 1California Northstate University, College of Medicine, Elk Grove, CA, USA; 2Retina Macula Institute, Torrance, CA, USACorrespondence: Ron P GallemoreRetina Macula Institute, 4201 Torrance Blvd., Ste 220 ...
Avaylon J, Lee S, Gallemore RP
doaj  

Anti-VEGFs for Diabetic Macular Oedema:Analysis of Efficacy, Safety, and Cost of More Durable Therapies from a Dutch Societal Perspective [PDF]

Introduction: Frequent intravitreal injections of anti-vascular endothelial growth factors (VEGFs) for diabetic macular oedema (DMO) pose challenges for healthcare systems, patients, and society.
Amarakoon, Sankha, Carrasco, Joao, Crossan, Catriona, Lunk, Izabella, Nikodem, Mateusz, Paulissen, Jeroen H.J., Pochopien, Michal, Postma, Maarten J., Quist, Sara W., van Asten, Freekje, Woudstra, Marrit A.   +10 more
core   +1 more source

Evidence for Whom? A Systematic Review of Eligibility Criteria in RCTs of Anti-VEGF for Neovascular Age-Related Macular Degeneration [PDF]

Purpose: To summarize the eligibility criteria used in randomized controlled trials (RCT) of intravitreal anti-VEGF treatments for neovascular age-related macular degeneration (AMD). Design: Systematic review. Methods: A search of 12 literature databases
Anguita, Rodrigo, Anjos, Rita Serrano, Arnold-Vangsted, Andreas, Butler, Emilie Theresa Sørrig, Cehofski, Lasse Jørgensen, Christensen, Vibeke, Desideri, Lorenzo Ferro, Grauslund, Jakob, Hajari, Javad Nouri, Kaya, Musa Yasin, Klefter, Oliver Niels, Lee, Celine, Petersen, Line, Rosenørn, Emil Alexander, Schneider, Miklos, Subhi, Yousif   +15 more
core   +4 more sources

Advancements in the Treatment of Diabetic Macular Edema: Current Strategies and Future Directions [PDF]

This narrative review examines current and emerging treatment strategies for diabetic macular edema (DME), a complication of diabetic retinopathy characterised by fluid accumulation in the macula, which can lead to vision impairment. The incidence of DME
Bachurska, Dominika, Czach, Magdalena, Czach, Zuzanna, Kopacz, Wojciech, Kruczyk, Barbara, Mazurek, Wojciech, Mazurek, Łukasz, Olędzka, Joanna, Piętak, Mateusz, Rękas, Barbara, Stradczuk , Monika   +10 more
core   +1 more source